METHOD DEVELOPMENT AND VALIDATION OF THE CHROMATOGRAPHIC ANALYSIS OF FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE COMBINATION IN SOLUTIONS AND HUMAN PLASMA USING HPLC WITH UV DETECTION
Keywords:Fluticasone Propionate, Salmeterol Xinafoate, HPLC, UV, Method Validation, Human Plasma
Objective: A simple, Rapid, and sensitive HPLC method utilizing UV detection was developed and validated for the simultaneous estimation of Fluticasone propionate (FP) and Salmeterol xinafoate (SX) in solutions and in vitro human plasma.
Methods: Chromatographic analysis was done on SUPELCO® RP-C18 column (150 x 4.6 mm, 5 μm particle size) with an isocratic mobile phase composed of methanol, acetonitrile, and water (50:20:30, v/v) mixture while flow rate was set to 1 ml/min. Detection with UV at maximum absorbance wavelength (ʎmax) values of 236 and 252 for FP and SX, respectively. Spiked plasma samples were liquid-liquid extracted by diethyl ether and reconstituted using methanol.
Results: Method was accurate and precise over a linear (R2>0.995) range of (0.067-100 µg/ml) and (0.0333-50 µg/ml) for FP and SX, respectively. LOD/lOQ values were 0.13/0.6 and 0.06/0.3 µg/ml for FP and SX, respectively.
The developed method was successfully applied for the analysis of FP and SX in spiked human plasma samples. The method is considered to be accurate and precise over a linear (R2>0.9969) range of (6.67-66.67 µg/ml) and (3.33-33.3 µg/ml) for FP and SX, respectively. Extraction efficiency was approved by recovery values of (94.98–102.46 %) and (96.54–102.62 %) for FP and SX, respectively.
Conclusion: This validated method revealed simple and cheap extraction procedures and detectors, non-buffered mobile phase, and short retention times with excellent resolution.
Shammout MJ, Başci NE. Validated ultra-performance liquid chromatography-tandem mass spectrometric method for determination of betamethasone or dexamethasone in pharmaceuticals. Curr Pharm Anal 2018;14:68-75.
Pelt AC. Glucocorticoids: effects, action mechanisms, and therapeutic uses. Hauppauge, N. Y.: Nova Science; 2011.
Ashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respi Res 2010;11:149.
Weersink EJ, Douma RR, Postma DS, Koeter GH. Fluticasone propionate, salmeterol xinafoate, and their combination in the treatment of nocturnal asthma. Am J Respir Crit Care Med 1997;155:1241-6.
Altaf M, Masood Q, Ahmed T, Ilyaz M, Basha S. Health related quality of life assessment using St. George’s respiratory questionnaire in chronic obstructive pulmonary patients on combined inhaled corticosteroids and bronchodilators. Int J Pharm Pharm Sci 2016;8:445-9.
Hammad MA, Omar MA, Awad M. Validation of sensitive spectrophotometric method for determination of salmeterol xinafoate and fenoterol hydrobromide via o-phenanthroline and iron complexation. J Appl Pharm Sci 2017;7:49-54.
Kondawar MS, Shah RR, Waghmare JJ, Malusare MK, Shah ND. UV spectrophotometric method for simultaneous estimation of salmeterol xinafoate and fluticasone propionate in bulk and dosage form. Int J Pharm Tech Res 2011;3:1801-6.
Lakshmi K, Kesareddy R, Babu S, Kota R, Karri R, Jafer Vali Shaik. Simultaneous estimation of fluticasone propionate, azelastine hydrochloride, phenylethyl alcohol, and benzalkonium chloride by RP-HPLC method in nasal spray preparations. Int J Res Pharm Sci 2010;1:473-80.
Samir A, Salem H, Abdelkawy M. Simultaneous determination of salmeterol xinafoate and fluticasone propionate in bulk powder and seretide diskus using high performance liquid chromatographic and spectrophotometric method. Pharm Anal Acta 2012;3:1-7.
Murnane D, Martin GP, Marriott C. Validation of a reverse-phase high performance liquid chromatographic method for concurrent assay of a weak base (salmeterol xinafoate) and a pharmacologically active steroid (fluticasone propionate). J Pharm Biomed Anal 2006;40:1149-54.
Jain S, Gorle AP, Patil SS, Chavan RS, Bari PR. Stability indicating RP-HPLC method for estimation of salmeterol xinafoate in bulk and pharmaceutical formulation. Int J Pharm Chem Anal 2015;2:28-33.
Shahanaz M, Vageesh NM, Nizamuddin ND, Hazra B. Development and validation of an RP-HPLC-PDA method for simultaneous determination of Fluticasone and Salmeterol in bulk and pharmaceutical dosage form. Int J Med Pharm Sci 2018;3:25-8.
Pączkowska E, Smukowska D, Tratkiewicz E, Białasiewicz P. HPLC method for simultaneous determination of salmeterol xinafoate and fluticasone propionate for the quality control of dry powder inhalation products. Acta Chromatogr 2015;27:309–20.
Masher HJ, Zech K, Masher DG. Sensitive simultaneous determination of ciclesonide, ciclesonide-M1-metabolite and fluticasone propionate in human serum by HPLC–MS/MS with APPI. J Chromatogr B: Anal Techno Biomed Life Sci 2008;869:84-92.
Van Eenoo P, Deventer K, Delbeke FT. Quantitative detection of salmeterol after inhalation in equine urine by liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2002;16:1755-9.
Mauro D, Ciardullo S, Civitareale C, Fiori M, Pastorelli AA, Stacchini P, et al. Development and validation of a multi-residue method for determination of 18 β-agonists in bovine urine by UPLC–MS/MS. Microchem J 2014;115:70-7.
Nair SG, Patel DP, Sanyal M, Singhal P, Shrivastav PS. Simultaneous analysis of glucocorticosteroids fluticasone propionate and its metabolite fluticasone propionate 17 β-carboxylic acid in human plasma by UPLC–MS/MS at sub pg/ml level. J Pharm Biomed Anal 2017;135:1-7.
Kulkarni PN, Jadhav CK, Dodake Supekar AM, Gill CH. The quality by design approach for simultaneous determination of fluticasone propionate and salmeterol xinafoate. Int J Appl Pharm 2020;12:70-6.
Kasaye L, Hymete A, Mohamed AM. HPTLC-densitometric method for simultaneous determination of salmeterol xinafoate and fluticasone propionate in dry powder inhalers. Saudi Pharm J 2010;18:153-9.
Rajashi B Pharate, Suneela S Dhaneshwar. Stability-indicating high-performance thin-layer chromatography method for simultaneous estimation of formoterol fumarate dihydrate and fluticasone propionate in bulk drug and pharmaceutical dosage form. Asian J Pharm Clin Res 2019;12:149-55.
Michael Y, Chowdhry B, Ashurst I, Snowden M, Davies Cutting C, Gray S. The Physico-chemical properties of salmeterol and fluticasone propionate in different solvent environments. Int J Pharm 2000;200:279-88.
Hauser B, Deschner T, Boesch C. Development of a liquid chromatography–Tandem mass spectrometry method for the determination of 23 endogenous steroids in small quantities of primate urine. J Chromatogr B 2008;862:100-12.
Food and Drug Administration; 2003. Guidance for Industry Q1A (R2): stability testing of new drug substances and products; 2003.
Gonzalez O, Alonso RM. Chapter 6-validation of bioanalytical chromatographic methods for the quantification of drugs in biological fluids. H and B Anal 2020;7:115-34.
International Conference on Harmonization (ICH) Harmonized Tripartite Guidelines, Validation of Analytical Procedures, Text, and Methodology, Q2 (R1), Parent Guidelines on Methodology; 1994.
SS Couto AR, Cardoso DE, Cabral Marques HM. Validation of an HPLC analytical method for the quantitative/qualitative determination of fluticasone propionate in inhalation particles on several matrices. Sci Pharm 2014;82:787-97.
Silvestro L, Savu SR, Savu SN, Tudoroniu A, Tarcomnicu I. Development of a sensitive method for simultaneous determination of fluticasone propionate and salmeterol in plasma samples by liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2012;26:627-35.
Duran A, Dogan HN, Ulgen M. Simultaneous quantitative determinations of fluticasone propionate and salmeterol xinafoate in diskus inhalers. Drug Metab Lett 2014;8:31-5.
Damle M, Choudhari S. Development and validation of stability indicating HPLC method for estimation of salmeterol xinafoate. J Pharm Qual Assur 2019;10:1865-9.
Cayır A, Cilen H, Sakızcı D, Turkyılmaz A. Method development and validation of simultaneous determination of related substances for salmeterol xinafoate and fluticasone propionate in dry powder inhalers. Chromatography Today 2017;4:14-9.
Acar S, Sakızcı D, Yilmaz E. Method development and validation of simultaneous determination of assay of salmeterol xinafoate and fluticasone propionate in dry powder inhalers. Chromatography Today 2020;3:32-6.
Krishnaswami S, Mollmann H, Derendorf H, Hochhaus G. A sensitive LC-MS/MS method for the quantification of fluticasone propionate in human plasma. J Pharm Biomed Anal 2000;22:123-9.